Creative medical technology holdings announces mid-term follow-up study data reporting significant reduction in opioid use by chronic lower back pain patients undergoing stemspine® procedure using allostem™

Phoenix, feb. 14, 2025 (globe newswire) -- creative medical technology holdings, inc. ("creative medical technology" or the "company") (nasdaq: celz), a pioneering biotechnology firm specializing in regenerative medicine solutions for immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced compelling mid-term follow-up data from its stemspine® pilot study utilizing its allostem™ cells for the treatment of chronic lower back pain. the pilot study demonstrated a substantial reduction in opioid dependency and significant improvements in pain levels and functional mobility.
CELZ Ratings Summary
CELZ Quant Ranking